secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001104659-24-093614
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics faces Nasdaq delisting over bid price and equity deficiencies; hearing Oct 1
--------------------------------------------------------------------------------

- Minimum Bid Price Deficiency Letter received Aug 13; stock below $1.00 for 30 consecutive days through Aug 12.
- Not eligible for compliance period due to two reverse stock splits in past two years with cumulative ratio >250:1.
- Stockholders' Equity Deficiency Letter received Aug 15; equity at June 30, 2024 was $1,322,274, below $2.5M requirement.
- Raised ~$2.4M in July 2024 equity offering; pro forma equity ~$3.7M, but no assurance Staff will accept pro forma.
- Nasdaq Hearing Panel will consider appeal on October 1, 2024; delisting action stayed pending decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924093614/0001104659-24-093614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924093614/tm2422872d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-093614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer